 Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: Phase 3 randomized trial | Second-line FOLFOX chemotherapy can significantly improve the prognosis of advanced cholangiocarcinoma

Lancet oncol: Phase 3 randomized trial | Second-line FOLFOX chemotherapy can significantly improve the prognosis of advanced cholangiocarcinoma

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

all red 4

25 kidney function

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The prognosis of advanced cholangiocarcinoma is poor.

This study aims to explore the therapeutic benefit of FOLFOX (leucovorin, fluorouracil and oxaliplatin) chemotherapy regimen as a second-line treatment in advanced cholangiocarcinoma

The ABC-06 clinical trial is a phase 3, open-label, randomized trial conducted in 20 locations in the United Kingdom, recruiting histologically confirmed locally advanced or metastatic bile ducts that have progressed after first-line cisplatin and gemcitabine chemotherapy at 18 years of age or older Patients with cancer (including gallbladder or ampullary cancer) were randomly divided into two groups at 1:1 and received FOLFOX chemotherapy and active symptom control (ASC) or only ASC.

Overall survival rate

From March 27, 2014 to January 4, 2018, a total of 162 patients were randomly assigned to the ASC+FOLFOX group or the single ASC group (81 patients each).

Compared with the single ASC group, the overall survival of the ASC+FOLFOX group was significantly prolonged.

Adverse events

The single ASC group and the ASC+FOLFOX group reported 42 (52%) and 56 (69%) grade 3-5 adverse events, including 3 chemotherapy-related deaths (deaths from infection , acute kidney injury, and febrile Neutropenia).

infection

All in all, on the basis of ASC, FOLFOX can increase the median overall survival (rate) of advanced cholangiocarcinoma patients who have progressed after treatment with cisplatin and gemcitabine.

On the basis of ASC, FOLFOX can improve the median overall survival (rate) of advanced cholangiocarcinoma patients who have progressed after treatment with cisplatin and gemcitabine, and the overall survival rate of 6 months and 12 months has a clinically significant increase.

Original source:

Angela Lamarca, et al.

org/10.
1016/S1470-2045(21)00027-9" target="_blank" rel="noopener">Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.